Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health CanadaGlobeNewsWire • Wednesday
Valneva Announces the Success of its Private Placement Raising approximately €60 MillionGlobeNewsWire • 09/13/24
Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million EurosGlobeNewsWire • 09/12/24
Pfizer and Valneva report positive results in mid-stage trial of Lyme disease vaccineMarket Watch • 09/03/24
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine CandidateGlobeNewsWire • 09/03/24
Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should KnowZacks Investment Research • 09/02/24
How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3%Zacks Investment Research • 08/15/24
Valneva Reports Half Year 2024 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 08/13/24
Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World's Most Clinically Advanced Tetravalent Shigella Vaccine CandidateGlobeNewsWire • 08/01/24
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 07/26/24
CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya VaccineGlobeNewsWire • 07/22/24
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026Benzinga • 07/18/24
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series CompletionGlobeNewsWire • 07/17/24
Valneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ®GlobeNewsWire • 07/01/24
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its BoardGlobeNewsWire • 06/26/24
Valneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ®GlobeNewsWire • 06/24/24
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate UpdateGlobeNewsWire • 06/05/24
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in JuneGlobeNewsWire • 06/04/24
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious DiseasesGlobeNewsWire • 06/03/24